Gary Weinstein, MD
Critical Care Medicine · Dallas, TXNPI 1275617920
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $94,550 of the $102,664 with a category attached, or 92.1%. GSK accounts for 96.1% of it on its own, with 36 other manufacturers making up the rest. Reporting peaked in 2024 at $35,948 and has fallen 93.9% since, to $2,196 in 2025. Among critical care medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $429.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$99K
- Boehringer Ingelheim$848
- AstraZeneca$645
- Inari Medical, Inc.$351
- AOP Health US, LLC$215
- Insmed, Inc.$206
- plus $2K from 31 others
Across 4 payments — averaging $4500.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$18K
What the payments were for
- Consulting fees$4050%
- Speaking & faculty fees$94,55092%
- Travel & lodging$2,1712%
- Food & beverage$5,4665%
- Education$720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 110 | $98,622 |
| Boehringer Ingelheim | 21 | $848 |
| AstraZeneca | 20 | $645 |
| Inari Medical, Inc. | 2 | $351 |
| AOP Health US, LLC | 1 | $215 |
| Insmed, Inc. | 9 | $206 |
| Grifols USA, LLC | 8 | $165 |
| Inspire Medical Systems, Inc. | 1 | $145 |
| Baxter Healthcare | 7 | $143 |
| Sanofi | 5 | $139 |
| Amgen | 5 | $99 |
| Merck | 4 | $75 |
| Lilly USA, LLC | 4 | $70 |
| Tactile Systems Technology Inc | 1 | $70 |
| Paratek Pharmaceuticals, Inc. | 4 | $68 |
| Electromed, Inc. | 4 | $67 |
| Philips North America LLC | 4 | $63 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| AbbVie | 2 | $55 |
| Resmed Corp | 1 | $54 |
| Actelion Pharmaceuticals US, Inc. | 2 | $48 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Viatris Specialty LLC | 2 | $43 |
| Verona Pharma, Inc. | 2 | $39 |
| Hospira, Inc. | 2 | $38 |
| Regeneron Healthcare Solutions, Inc. | 1 | $37 |
| Caris MPI, Inc. | 1 | $33 |
| United Therapeutics Corporation | 1 | $32 |
| Pfizer | 2 | $32 |
| Vapotherm Inc | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $26 |
| Itamar Medical Inc | 1 | $22 |
| Hikma Pharmaceuticals USA | 1 | $21 |
| Johnson & Johnson | 1 | $17 |
| Inogen, Inc. | 1 | $16 |
| CSL Behring | 1 | $15 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AREXVY$34,351
- TRELEGY ELLIPTA$29,136
- Rapiblyk$429
- SPIRIVA$405
- FLOWTRIEVER CATHETER, S$351
- CT THROMBECTOMY SYSTEM KIT$351
- FASENRA$335
- Inspire$145
- OFEV$123
- NUCALA$116
How this compares
$102,664 in reported general payments places this provider in the 95th percentile of 507 critical care medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 655 | $488,628 |
| Pirfenidone | 33 | $70,788 |
| Breo ElliptaFluticasone/Vilanterol | 106 | $51,158 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $46,905 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 36 | $27,365 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 28 | $18,725 |
| Spiriva RespimatTiotropium Bromide | 24 | $16,960 |
| Arnuity ElliptaFluticasone Furoate | 46 | $11,049 |
| Roflumilast | 94 | $6,240 |
| Montelukast Sodium | 446 | $4,264 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $4,181 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,616 |
| DuleraMometasone/Formoterol | 11 | $3,558 |
| Azelastine Hcl | 87 | $3,511 |
| RyaltrisOlopatadine Hcl/Mometasone | 12 | $3,449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $98,622 | $597,740870 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $848 | $35,68552 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $645 | $30,08148 claims |
| MerckDulera | $75 | $3,55811 claims |
| Hikma Pharmaceuticals USARyaltris | $21 | $3,44912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 critical care medicine providers in Texas.
Other critical care medicine in Dallas
- Anthony OrtegonDallas$106K
- Thomas ArdilesDallas$47K
- Rebecca DoebeleDallas$12K
- Humayun AnjumDallas$11K
- Sridhar BadireddiDallas$11K
- David PhamDallas$10K
- Jake RiceDallas$9K
- Bryan KellyDallas$9K
- Munir HazbunDallas$8K
- Steven DavidoffPlano$364K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.